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Background: Recently, the role of monoacylglycerol lipase (MAGL) as the principal regulator of simultaneous
prostaglandin synthesis and endocannabinoid receptor activation in the CNS was demonstrated. To expand upon
previously published research in the field, we observed the effect of the MAGL inhibitor JZL184 during the early-stage
proinflammatory response and formation of beta-amyloid (Aβ) in the Alzheimer’s disease mouse model APdE9. We also
investigated its effects in proinflammatory agent - induced astrocytes and microglia isolated from adult mice.
Findings: Transgenic APdE9 mice (5 months old) were treated with JZL184 (40 mg/kg) or vehicle every day for
1 month. In vivo binding of the neuroinflammation-related, microglia-specific translocator protein (TSPO) targeting
radioligand [18 F]GE-180 decreased slightly but statistically non-significantly in multiple brain areas compared to
vehicle-treated mice. JZL184 treatment induced a significant decrease in expression levels of inflammation-induced,
Iba1-immunoreactive microglia in the hippocampus (P < 0.01) and temporal and parietal (P < 0.05) cortices. JZL184 also
induced a marked decrease in total Aβ burden in the temporal (P < 0.001) and parietal (P < 0.01) cortices and, to some
extent, in the hippocampus. Adult microglial and astrocyte cultures pre-treated with JZL184 and then exposed to the
neuroinflammation-inducing agents lipopolysaccharide (LPS), interferon-gamma (IFN-γ), and Aβ42 had significantly
reduced proinflammatory responses compared to cells without JZL184 treatment.
Conclusions: JZL184 decreased the proinflammatory reactions of microglia and reduced the total Aβ burden and its
precursors in the APdE9 mouse model. It also reduced the proinflammatory responses of microglia and astrocytes
isolated from adult mice.
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During early-stage Alzheimer’s disease (AD), the neu-
roinflammatory responses of hyperactivated glial cells
have a major impact on the development of AD path-
ology, including the formation of neurotoxic beta-
amyloid (Aβ) [1,2]. Suppressing inflammatory signaling
has had beneficial effects in animal models of AD [3].
On the other hand, molecular imaging of neuroinflam-
mation may be employed for the early diagnosis of AD
and to evaluate the patient’s response to treatment.* Correspondence: rea.pihlaja@utu.fi
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unless otherwise stated.In the brain, the production of proinflammatory pros-
taglandins is mainly regulated by the activity of monoa-
cylglycerol lipase (MAGL) [4]. MAGL hydrolyzes the
anti-inflammatory and neuroprotective endocannabinoid
2-arachidonoylglycerol (2-AG) to arachidonic acid (AA),
which is further metabolized to prostaglandins. Inhib-
ition of MAGL by genetic manipulation or the MAGL
inhibitor JZL184 reduces the levels of AA and its prosta-
glandin metabolites E2 and D2. Inhibition of MAGL also
increases levels of 2-AG in the brain. Both of these
mechanisms are associated with neuroprotection in a
parkinsonian mouse model and alleviation of lipopolysac-
charide (LPS)-induced neuroinflammation. Moreover,
pharmacological [5] and genetic [6] inactivation of MAGLThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and improves cognitive function in the AD mouse models
5XFAD and PS1APP. To date, of the MAGL inhibitors,
JZL184 has been the most thoroughly characterized
in vivo; thus, this compound is widely used as a preclinical
tool [7].
We extended the findings of previous studies by in-
vestigating the effect of JZL184 on the early-stage pro-
inflammatory response and Aβ deposition in APPSwe/
PSEN1dE9 (APdE9) [8] mice. The level of activated micro-
glia in JZL184- and vehicle-treated mice was determined
by positron emission tomography-computed tomography
(PET/CT). Levels of gliosis and total Aβ were determined
by immunohistochemistry. In addition, we studied the
effect of JZL184 in glial cultures isolated from adult mice
under conditions that mimic neuroinflammation.
In 3.5-month-old APdE9 mice, levels of proinflamma-
tory mediators are correlated with soluble Aβ levels. By
the age of 6 months, the proinflammatory responses of
glial cells notably increased and the first Aβ deposits
have formed [2]. For in vivo studies, we used 5-month-
old female APdE9 mice. The studies were approved by the
Animal Experiment Board of the Province of Southern
Finland (licence number ESAVI-2010-04454/Ym-23).
JZL184 (Cayman Chemical Company, Ann Arbor, MI,
USA) formulation was prepared in an 18:1:1 solution of
saline:emulphor:ethanol, as previously described [7]. Every
day for 1 month, 40 mg/kg JZL184 was injected intraperi-
toneally into tg APdE9 mice (n = 7). Vehicle-treated tg
APdE9 mice (n = 5) were used as controls.
Mice were anesthetized with 2.5% isoflurane, and 15 ±
2 MBq of radioligand [18 F]GE-180 [9] was injected
intravenously. A 60-min dynamic PET/CT scan (Inveon
multimodality PET/CT device; Siemens Medical Solu-
tions, Malvern, PA, USA) was started immediately after
injection (3D list mode; energy window of 350 to
650 keV; and 52 time frames: 30 × 10, 15 × 60, 4 × 300,
and 2 × 600 s). Transmission scans were performed with
CT for attenuation correction. Data were reconstructed
with Fourier rebinning and a 2D-filtered back-projection
reconstruction algorithm. Inveon Research Workplace
Image Analysis software (Siemens Medical Solutions)
was used to draw regions of interest (ROIs) over the
whole brain, the cerebellum, and the entire cortex and
separately over the frontal and parieto-temporal cortex,
hippocampus, striatum, and thalamus. A 3D MRI template
was used as an anatomical reference. Time-radioactivity
curves were used to express the uptake of [18 F]GE-180 as
% ID/g, and target-to-cerebellum ratios were calculated.
In JZL184-treated mice, there was a very slight decreasing
trend in translocator protein (TSPO) signal in multiple
ROIs (for example, in the hippocampus, Figure 1B) com-
pared to vehicle-treated mice. However, the difference was
not statistically significant.All JZL184 (n = 7) and vehicle (n = 5)-treated mice
were anesthetized and transcardially perfused with hepa-
rinized saline. The cortex, hippocampus, and cerebellum
were then isolated from the right hemisphere and snap
frozen in liquid nitrogen. The left hemisphere was post-
fixed with 4% paraformaldehyde solution, cryoprotected
in 30% sucrose, snap frozen in liquid nitrogen, and
stored at −70°C. Processing of the brain tissue and im-
munohistochemistry were performed as described previ-
ously [10], using the mouse beta-amyloid monoclonal
antibody 6E10 (Covance Inc., Princeton, NJ, USA) and a
polyclonal rabbit anti-glial fibrillary acidic protein (GFAP)
antibody (Dako Cytomation, Glostrup, Denmark) that rec-
ognizes activated astrocytes or a rabbit polyclonal anti-
Iba1 antibody (WAKO Pure Chemical Industries, Ltd.,
Osaka, Japan). The 6E10 antibody recognizes amino acid
residues 1–16 in various abnormally processed isoforms of
intra- and extracellular human Aβ [11-15], as well as
amyloid precursors. Alexa Fluor 568-conjugated goat anti-
rabbit (Gibco, Carlsbad, CA, USA) or donkey anti-mouse
IgG (Dylight 488, Abcam, Cambridge, UK) were used as
secondary antibodies. Images were acquired with the Leica
DMR fluorescence microscope (Leica Microsystems
GmbH, Wetzlar, Germany) and ISCapture software 2.6
(Fuzhou Xintu Photonics Co, Ltd., Fujian, China); settings
were kept constant for quantitation. Six or seven sections
per mouse with five to seven areas per section were im-
aged throughout the hippocampal formation. The areas
examined were the temporal and parietal cortices and the
hippocampus (including CA1, CA2, and DG). The quanti-
fication was performed using per area (%) method (Image
J 1.43 U, Wayne Rasband, NIH, MA, USA).
Levels of Iba1 expression were decreased in JZL184-
treated mice in the temporal and parietal cortices (by
49% and 46%, respectively; P < 0.05) and in the hippo-
campus (by 57%, P < 0.01) compared to vehicle-treated
mice (Figures 1A and 2A, E, I, M). Similarly, expression
levels of GFAP decreased slightly but not significantly
in all of the regions examined (Figure 1C). Levels of
6E10 immunoreactivity were reduced significantly in
the temporal (by 79%, P < 0.001) and parietal (by 67%,
P < 0.01) cortices and, to some extent, in the hippocam-
pus compared to vehicle-treated mice (Figures 1D and
2B, F, J, N).
A human Aβ42 enzyme-linked immunosorbent assay
(ELISA) was performed for the hippocampi and cortices
isolated from the APdE9 mice, in accordance with the
protocol for the Aβ42 Human ELISA Kit (Biosource
International/Invitrogen, Carlsbad, CA, USA). Expres-
sion levels of Aβ42 in the hippocampus and cortex in
ELISA did not differ between JZL184- and vehicle-
treated tg APdE9 mice (data not shown). In contrast to
6E10 antibody, Aβ42 antibody in ELISA recognizes only









































































Figure 1 (See legend on next page.)
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Figure 1 JZL184 treatment reduced the level of microgliosis and total Aβ in the AD mouse model. One month daily treatment with JZL184
(40 mg/kg, i.p.) reduced the immunoreactivity of (A) Iba1 in temporal (TC) (P < 0.05) and parietal (PC) (P < 0.05) cortices and hippocampus
(HC) (P < 0.01) in 5-month-old tg APdE9 mice when compared to vehicle-treated mice. Also, (B) TSPO targeting radioligand [18 F]GE-180 decreased
slightly but statistically non-significantly in multiple brain areas, for example, in the hippocampi. The level of (C) GFAP did not decrease significantly.
The level of (D) 6E10 was reduced in TC (P < 0.001) and PC (P < 0.01) and slightly in HC.
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astrocytes were cultured according to the procedures
outlined in [16] and [17], respectively. Three days be-
fore exposure, the cells were seeded (2 × 104 cells/well)
into 48-well plates in the absence of recombinant mur-
ine granulocyte-macrophage colony-stimulating factor
(rmGM-CSF) and G5 supplement.
Homogenous Aβ42 (American Peptide Company,
Sunnyvale, CA, USA) oligomers were prepared ac-
cording to protocol by Dahlgren et al. [18]. For cell
culture assays, the wells containing adult microglia














Figure 2 The level of microgliosis and total Aβ burden in JZL184 and vehicle
Iba1 immunoreactivity in (A, E) temporal cortex (TC) and (I, M) hippocampus
tg APdE9 mice when compared to mice treated with vehicle only. Merged im
responsive areas in D, H, L and P. Scale bars indicate 500 μM.incubated for 30 min in the presence or absence of
1 μM JZL184, and then exposed to 10 μM Aβ42 or a
combination of 1 μM LPS and 100 ng/ml interferon-
gamma (IFN-γ) for 24 h. The medium was collected
for nitric oxide (NO) measurement, and the cells were
fixed with 3.7% formaldehyde, rinsed, and stored in
phosphate-buffered saline (PBS).
The concentration of NO in the cell medium was mea-
sured by Griess reaction according to the manufacturer’s
instructions (Sigma-Aldrich). Fifty microliters of Griess re-
agent was then added to each well. The plate was shaken








-treated tg APdE9 mice. Similar to Figure 1, JZL184 treatment reduced
(HC) and 6E10 immunoreactivity in (B, F) TC and slightly in (J, N) HC of
ages from TC (C, G) and from HC (K, O). DAPI-stained nuclei from the
Pihlaja et al. Journal of Neuroinflammation  (2015) 12:81 Page 5 of 6(Wallac Victor2 V 1420; Wallac Oy, Finland). Levels of se-
creted IL-1β were determined by ELISA according to the
manufacturer’s instructions (Biosource International/Invi-
trogen). Simultaneous exposure to LPS and IFN-γ was as-























































































































Figure 3 JZL184 decreased secretion of NO and IL-1β from adult glial cells
pre-incubated with MAGL inhibitor JZL184 for 30 min before inducing proi
100 ng/ml IFN-γ. After 24 h of incubation, secretion of NO was reduced (A)
with JZL184 compared to exposed cells w/o JZL184 treatment. JZL184 induce
but (D) did not have an effect on astrocytes compared to cells w/o JZL184 tre
expression slightly in microglia and astrocytes induced with LPS and IFN-γ anand IL-1β in both microglia and astrocytes, compared to
unexposed cells (Figure 3A, B, C, D). A 30 min pre-
treatment with JZL184 decreased NO secretion slightly in
microglia (Figure 3A) and significantly in astrocytes (P <





























































































































exposed to proinflammatory agents. Astrocytes and microglia were
nflammatory responses by simultaneous exposure of 1 μM LPS and
slightly in microglia and (B) significantly (P < 0.01) in astrocytes treated
d (C) a marked reduction in IL-1β secretion from microglia (P < 0.001)
atment. Pre-treatment with JZL184 decreased (E) Iba1 and (F) GFAP
d significantly in microglia and astrocytes induced with Aβ42 (P < 0.01).
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in microglia (P < 0.001, Figure 3C) but not in astrocytes
(Figure 3D) compared to cells w/o JZL184 treatment.
For immunocytochemistry, fixed cells were blocked
with 10% normal goat serum (NGS) (Chemicon) in PBS
with Tween-20 (PBST), incubated overnight with either
anti-GFAP (in 5% NGS in PBST) or anti-Iba1-antibodies,
and washed in PBST 3× for 5 min. The secondary anti-
bodies, Alexa Fluor 568 goat anti-rabbit antibody (Gibco)
or donkey anti-mouse IgG (Dylight 488, Abcam), were
added to the cells, incubated for 2 h RT, washed, em-
bedded in mounting medium, and imaged with a Zeiss
Axiovert 200 M microscope, a Zeiss Axiovert MRc cam-
era, and Axiovision 4.8 software (Zeiss International,
Oberkochen, Germany). Four microscopic fields and four
to five wells per cell type were analyzed for the percentage
of anti-GFAP or anti-Iba immunostained cells, quantified
using per area (%) method (Image J 1.43 U).
Aβ42 or simultaneous LPS and IFN-γ exposure in-
creased Iba1 and GFAP expression. Pre-treatment with
JZL184 decreased Iba1 expression significantly in micro-
glia induced with Aβ42 (P < 0.01) and slightly when in-
duced with LPS and IFN-γ (Figure 3E). Similarly, JZL184
pre-treatment significantly reduced GFAP expression in
astrocytes induced with Aβ42 (P < 0.01) and slightly
when induced with LPS and IFN-γ (Figure 3F).
The data were analyzed with t-test, one-way ANOVA
with Tukey’s multiple comparison test, or Mann–Whitney
U-test with GraphPad Prism v4.0. Significance was as-
sumed if the P value was <0.05.
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